INHIBRX BIOSCIENCES, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- INHIBRX BIOSCIENCES, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $1.60M.
- INHIBRX BIOSCIENCES, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $471.00K.
- INHIBRX BIOSCIENCES, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $352.00K.
- INHIBRX BIOSCIENCES, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $31.30M, a 3565.11% increase year-over-year.
- INHIBRX BIOSCIENCES, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $1.61M, a 97.76% decline from fiscal 2024.
- INHIBRX BIOSCIENCES, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $71.68M, a 2994.91% increase from fiscal 2023.
- INHIBRX BIOSCIENCES, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $2.32M.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $1.60M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $471.00K 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $1.61M 10-K · filed 2026-03-19 | |
| 2025-09-30 | $352.00K 10-Q · filed 2025-11-14 | |
| 2024-12-31 | $71.68M 10-K · filed 2026-03-19 | |
| 2024-06-30 | $31.30M 10-Q · filed 2025-11-14 | |
| 2024-03-31 | $40.38M 10-Q · filed 2025-11-14 | |
| 2023-12-31 | $2.32M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $21.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $854.00K 10-Q · filed 2024-11-14 | |
| 2023-03-31 | $356.00K 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |